Shares of FibroGen Inc. (NASDAQ:FGEN) shot up 1.8% during mid-day trading on Friday . The stock traded as high as $18.94 and last traded at $18.78, with a volume of 112,137 shares changing hands. The stock had previously closed at $18.45.

Several brokerages recently issued reports on FGEN. Zacks Investment Research downgraded FibroGen from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Credit Suisse Group AG reiterated a “buy” rating on shares of FibroGen in a report on Wednesday, May 25th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $33.25.

The firm’s 50 day moving average is $17.73 and its 200 day moving average is $18.35. The firm’s market capitalization is $1.20 billion.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. Analysts predict that FibroGen Inc. will post ($1.24) EPS for the current fiscal year.

In other FibroGen news, CFO Pat Cotroneo sold 1,796 shares of the company’s stock in a transaction on Wednesday, June 15th. The stock was sold at an average price of $16.49, for a total value of $29,616.04. Following the transaction, the chief financial officer now owns 138,114 shares of the company’s stock, valued at approximately $2,277,499.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Thomas B. Neff sold 27,000 shares of the company’s stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $18.99, for a total value of $512,730.00. Following the completion of the transaction, the chief executive officer now directly owns 3,507,164 shares in the company, valued at approximately $66,601,044.36. The disclosure for this sale can be found here.

A number of institutional investors have made changes to their positions in FGEN. Cornerstone Capital Management Holdings LLC. acquired a new position in shares of FibroGen during the fourth quarter valued at approximately $3,067,000. California Public Employees Retirement System acquired a new position in shares of FibroGen during the fourth quarter valued at approximately $3,397,000. Rhumbline Advisers increased its position in FibroGen by 8.7% in the fourth quarter. Rhumbline Advisers now owns 45,940 shares of the biopharmaceutical company’s stock worth $1,400,000 after buying an additional 3,675 shares during the last quarter. Finally, Swiss National Bank increased its position in FibroGen by 1.8% in the fourth quarter. Swiss National Bank now owns 63,400 shares of the biopharmaceutical company’s stock worth $1,932,000 after buying an additional 1,100 shares during the last quarter.

FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.